Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amid Warfarin Inertia, Bristol/Pfizer Price Eliquis On Par With Pradaxa

This article was originally published in The Pink Sheet Daily

Executive Summary

Eliquis is set to become widely available in the U.S. market at the end of January, with pricing similar to other new oral anticoagulants, despite competitive advantages. Cost and safety concerns help explain why warfarin continues to dominate the market.

You may also be interested in...



More Pressure On Pradaxa? US Payers May Narrow Coverage Of NOACs

US payers may increasingly look to leverage the competition among the novel oral anticoagulants by contracting for preferred coverage with two of the leading drugs in the field, rather than all three.

Eliquis Poised To Wake Up U.S. Oral Anticoagulant Market

Bad press and lawsuits related to bleeding events for Boehringer Ingelheim’s novel anticoagulant Pradaxa create a window of opportunity for Eliquis, which is pending approval in the U.S. and could have what it takes to tip the market away from generic warfarin.

Mini Sentinel Alleviates FDA Concern Over Pradaxa Bleeding Issue

Data from the pilot program a “driving factor” in the agency’s decision against changing its recommendations for the blood thinner following reports of increased serious bleeding events.

Topics

Related Companies

UsernamePublicRestriction

Register

PS074784

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel